Emerging microbial-based therapeutic solutions

Companies developing microbiome-based therapies have been beset by challenges in the past few years, but hopes remain for some applications and could soon be boosted by the first regulatory approval in the field.

Solarea Bio is harnessing the diversity of the edible plant microbiota to deliver medical food products that aid the dietary management of inflammatory disorders and support healthy aging.

Using innovative particle-engineering technology, Alveolus Bio is developing a platform that delivers live biotherapeutic products deep into the lungs for the treatment of chronic and infectious respiratory disease.

Microbiotica’s platform makes it a leader in precision clinical discovery of novel microbiome-based therapeutics and biomarkers. With the platform validated at scale, and a pipeline of programs, the company is open to collaborations in both therapeutic and biomarker discovery.

How a 100-year-old study spawned a novel class of multifunctional neurological treatments.

With Exeliom Biosciences’s drug candidate, EXL01, the long-touted immune-modulation potential of a key gut bacterial species is finally reaching patients in the clinic.

Australia’s Microba is leveraging its world-leading microbiome tools and data science for rigorous hypothesis-driven live-biotherapeutics development.